{"id":991510,"date":"2026-02-20T13:03:03","date_gmt":"2026-02-20T13:03:03","guid":{"rendered":"https:\/\/ukpostcode.org\/content\/?p=991510"},"modified":"2026-02-20T13:03:03","modified_gmt":"2026-02-20T13:03:03","slug":"abpi-report-warns-preclinical-model-limitations-are-slowing-uk-innovation","status":"publish","type":"post","link":"https:\/\/ukpostcode.org\/content\/abpi-report-warns-preclinical-model-limitations-are-slowing-uk-innovation\/","title":{"rendered":"ABPI report warns preclinical model limitations are slowing UK innovation"},"content":{"rendered":"<p>&nbsp;<\/p>\n<hr \/>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_73 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/ukpostcode.org\/content\/abpi-report-warns-preclinical-model-limitations-are-slowing-uk-innovation\/#_What_the_ABPI_Report_Is_About\" title=\"\u00a0What the ABPI Report Is About\">\u00a0What the ABPI Report Is About<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/ukpostcode.org\/content\/abpi-report-warns-preclinical-model-limitations-are-slowing-uk-innovation\/#_Why_Pre-Clinical_Models_Matter\" title=\"\u00a0Why Pre-Clinical Models Matter\">\u00a0Why Pre-Clinical Models Matter<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/ukpostcode.org\/content\/abpi-report-warns-preclinical-model-limitations-are-slowing-uk-innovation\/#_Key_Problems_Identified\" title=\"\u00a0Key Problems Identified\">\u00a0Key Problems Identified<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/ukpostcode.org\/content\/abpi-report-warns-preclinical-model-limitations-are-slowing-uk-innovation\/#1_Limited_Predictivity_and_Translation_to_Humans\" title=\"1. Limited Predictivity and Translation to Humans\">1. Limited Predictivity and Translation to Humans<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/ukpostcode.org\/content\/abpi-report-warns-preclinical-model-limitations-are-slowing-uk-innovation\/#2_Infrastructure_Resource_Gaps\" title=\"2. Infrastructure &amp; Resource Gaps\">2. Infrastructure &amp; Resource Gaps<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/ukpostcode.org\/content\/abpi-report-warns-preclinical-model-limitations-are-slowing-uk-innovation\/#3_Need_for_Better_Coordination\" title=\"3. Need for Better Coordination\">3. Need for Better Coordination<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/ukpostcode.org\/content\/abpi-report-warns-preclinical-model-limitations-are-slowing-uk-innovation\/#_Impacts_on_UK_Innovation\" title=\"\u00a0Impacts on UK Innovation\">\u00a0Impacts on UK Innovation<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/ukpostcode.org\/content\/abpi-report-warns-preclinical-model-limitations-are-slowing-uk-innovation\/#_Slowed_Medicine_Discovery\" title=\"\u00a0Slowed Medicine Discovery\">\u00a0Slowed Medicine Discovery<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/ukpostcode.org\/content\/abpi-report-warns-preclinical-model-limitations-are-slowing-uk-innovation\/#_Reduced_Competitiveness\" title=\"\u00a0Reduced Competitiveness\">\u00a0Reduced Competitiveness<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/ukpostcode.org\/content\/abpi-report-warns-preclinical-model-limitations-are-slowing-uk-innovation\/#_Case-Level_Insights\" title=\"\u00a0Case-Level Insights\">\u00a0Case-Level Insights<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/ukpostcode.org\/content\/abpi-report-warns-preclinical-model-limitations-are-slowing-uk-innovation\/#_Human-Relevant_In_Vitro_Models\" title=\"\u00a0Human-Relevant In Vitro Models\">\u00a0Human-Relevant In Vitro Models<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/ukpostcode.org\/content\/abpi-report-warns-preclinical-model-limitations-are-slowing-uk-innovation\/#_Computer-Based_Modelling\" title=\"\u00a0Computer-Based Modelling\">\u00a0Computer-Based Modelling<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/ukpostcode.org\/content\/abpi-report-warns-preclinical-model-limitations-are-slowing-uk-innovation\/#_Reactions_Expert_Comments\" title=\"\u00a0Reactions &amp; Expert Comments\">\u00a0Reactions &amp; Expert Comments<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/ukpostcode.org\/content\/abpi-report-warns-preclinical-model-limitations-are-slowing-uk-innovation\/#_Industry_Experts\" title=\"\u00a0Industry Experts\">\u00a0Industry Experts<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/ukpostcode.org\/content\/abpi-report-warns-preclinical-model-limitations-are-slowing-uk-innovation\/#_Why_It_Matters_for_the_UK\" title=\"\u00a0Why It Matters for the UK\">\u00a0Why It Matters for the UK<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/ukpostcode.org\/content\/abpi-report-warns-preclinical-model-limitations-are-slowing-uk-innovation\/#_In_Summary\" title=\"\u00a0In Summary\">\u00a0In Summary<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/ukpostcode.org\/content\/abpi-report-warns-preclinical-model-limitations-are-slowing-uk-innovation\/#_What_the_ABPI_Report_Says\" title=\"\u00a0What the ABPI Report Says\">\u00a0What the ABPI Report Says<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/ukpostcode.org\/content\/abpi-report-warns-preclinical-model-limitations-are-slowing-uk-innovation\/#_Key_Findings_Translational_Challenges\" title=\"\u00a0Key Findings &amp; Translational Challenges\">\u00a0Key Findings &amp; Translational Challenges<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-19\" href=\"https:\/\/ukpostcode.org\/content\/abpi-report-warns-preclinical-model-limitations-are-slowing-uk-innovation\/#_1_%E2%80%9CTranslational_Gap%E2%80%9D_from_Lab_to_Industry\" title=\"\u00a01. \u201cTranslational Gap\u201d from Lab to Industry\">\u00a01. \u201cTranslational Gap\u201d from Lab to Industry<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-20\" href=\"https:\/\/ukpostcode.org\/content\/abpi-report-warns-preclinical-model-limitations-are-slowing-uk-innovation\/#_Case-Driven_Insights\" title=\"\u00a0Case-Driven Insights\">\u00a0Case-Driven Insights<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-21\" href=\"https:\/\/ukpostcode.org\/content\/abpi-report-warns-preclinical-model-limitations-are-slowing-uk-innovation\/#_Advanced_Human_Cell_Models\" title=\"\u00a0Advanced Human Cell Models\">\u00a0Advanced Human Cell Models<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-22\" href=\"https:\/\/ukpostcode.org\/content\/abpi-report-warns-preclinical-model-limitations-are-slowing-uk-innovation\/#_In_Silico_Computer_Modelling\" title=\"\u00a0In Silico (Computer) Modelling\">\u00a0In Silico (Computer) Modelling<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-23\" href=\"https:\/\/ukpostcode.org\/content\/abpi-report-warns-preclinical-model-limitations-are-slowing-uk-innovation\/#_Expert_Stakeholder_Comments\" title=\"\u00a0Expert &amp; Stakeholder Comments\">\u00a0Expert &amp; Stakeholder Comments<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-24\" href=\"https:\/\/ukpostcode.org\/content\/abpi-report-warns-preclinical-model-limitations-are-slowing-uk-innovation\/#_Academic_Industry_Experts\" title=\"\u00a0Academic &amp; Industry Experts\">\u00a0Academic &amp; Industry Experts<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-25\" href=\"https:\/\/ukpostcode.org\/content\/abpi-report-warns-preclinical-model-limitations-are-slowing-uk-innovation\/#_Community_Commentary_Context\" title=\"\u00a0Community &amp; Commentary Context\">\u00a0Community &amp; Commentary Context<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-26\" href=\"https:\/\/ukpostcode.org\/content\/abpi-report-warns-preclinical-model-limitations-are-slowing-uk-innovation\/#_What_This_Means_for_UK_Innovation\" title=\"\u00a0What This Means for UK Innovation\">\u00a0What This Means for UK Innovation<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-27\" href=\"https:\/\/ukpostcode.org\/content\/abpi-report-warns-preclinical-model-limitations-are-slowing-uk-innovation\/#_Slower_Time-to-Clinic\" title=\"\u00a0Slower Time-to-Clinic\">\u00a0Slower Time-to-Clinic<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-28\" href=\"https:\/\/ukpostcode.org\/content\/abpi-report-warns-preclinical-model-limitations-are-slowing-uk-innovation\/#_Reduced_Investment_Appeal\" title=\"\u00a0Reduced Investment Appeal\">\u00a0Reduced Investment Appeal<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-29\" href=\"https:\/\/ukpostcode.org\/content\/abpi-report-warns-preclinical-model-limitations-are-slowing-uk-innovation\/#_Missed_Collaborative_Potential\" title=\"\u00a0Missed Collaborative Potential\">\u00a0Missed Collaborative Potential<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-30\" href=\"https:\/\/ukpostcode.org\/content\/abpi-report-warns-preclinical-model-limitations-are-slowing-uk-innovation\/#_In_Summary-2\" title=\"\u00a0In Summary\">\u00a0In Summary<\/a><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"_What_the_ABPI_Report_Is_About\"><\/span>\u00a0What the ABPI Report Is About<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The ABPI and academic partners have published a <strong>landscape review of pre-clinical model development in the UK<\/strong> \u2014 focusing on how well these models replicate human biology for research and drug discovery. Pre-clinical models include animal studies, <strong>in vitro<\/strong> (cell, tissue) systems, and <strong>in silico<\/strong> (computer-based simulations) models that are used before testing new drugs in humans. (<a title=\"From models to medicines: a landscape review of human-relevant pre-clinical model development in the UK\" href=\"https:\/\/www.abpi.org.uk\/publications\/from-models-to-medicines-a-landscape-review-of-human-relevant-pre-clinical-model-development-in-the-uk\/?utm_source=chatgpt.com\">ABPI<\/a>)<\/p>\n<p>The report finds that while the UK has <strong>strong scientific expertise<\/strong>, there are <strong>major gaps in capacity, coordination and adoption of advanced human-relevant models<\/strong>, which is slowing the ability to translate research into real medicines. (<a title=\"UK: Industry Needs To Work With Academia On Pre-Clinical \u2018Translational Gap\u2019\" href=\"https:\/\/insights.citeline.com\/pink-sheet\/r-and-d\/uk-industry-needs-to-work-with-academia-on-pre-clinical-translational-gap-FKQS3QIU3NDS3GR2BKMMVM3LZQ\/?utm_source=chatgpt.com\">Insights<\/a>)<\/p>\n<hr \/>\n<h2><span class=\"ez-toc-section\" id=\"_Why_Pre-Clinical_Models_Matter\"><\/span>\u00a0Why Pre-Clinical Models Matter<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>In drug development, companies use pre-clinical models to:<\/p>\n<ul>\n<li>Understand <strong>human disease biology<\/strong><\/li>\n<li>Identify and refine <strong>drug targets<\/strong><\/li>\n<li>Test <strong>safety and early effectiveness<\/strong> before clinical trials<\/li>\n<\/ul>\n<p>Accurate models reduce the chance that drugs will fail in costly clinical testing. Poorly predictive models mean more candidates fail later, slowing innovation and spending more time and money. (<a title=\"From models to medicines: a landscape review of human-relevant pre-clinical model development in the UK\" href=\"https:\/\/www.abpi.org.uk\/publications\/from-models-to-medicines-a-landscape-review-of-human-relevant-pre-clinical-model-development-in-the-uk\/?utm_source=chatgpt.com\">ABPI<\/a>)<\/p>\n<hr \/>\n<h2><span class=\"ez-toc-section\" id=\"_Key_Problems_Identified\"><\/span>\u00a0Key Problems Identified<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"1_Limited_Predictivity_and_Translation_to_Humans\"><\/span>1. <strong>Limited Predictivity and Translation to Humans<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<ul>\n<li>Many existing models fail to realistically mimic <strong>human biology and disease mechanisms<\/strong>, leading to a \u201ctranslational gap\u201d \u2014 meaning promising findings don\u2019t reliably translate into human outcomes.<\/li>\n<li>This contributes to <strong>high attrition rates<\/strong> in drug development and slows the pace at which new medicines reach patients. (<a title=\"From models to medicines:\" href=\"https:\/\/www.abpi.org.uk\/media\/033jwbjj\/models-to-medicines-feb-2026.pdf?utm_source=chatgpt.com\">ABPI<\/a>)<\/li>\n<\/ul>\n<hr \/>\n<h3><span class=\"ez-toc-section\" id=\"2_Infrastructure_Resource_Gaps\"><\/span>2. <strong>Infrastructure &amp; Resource Gaps<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<ul>\n<li>There are <strong>shortages in technical platforms and specialist facilities<\/strong> needed to develop, validate and scale advanced in vitro and in silico models.<\/li>\n<li>Without well-supported facilities, <strong>industry adoption lags behind innovation created in academia<\/strong>. (<a title=\"UK: Industry Needs To Work With Academia On Pre-Clinical \u2018Translational Gap\u2019\" href=\"https:\/\/insights.citeline.com\/pink-sheet\/r-and-d\/uk-industry-needs-to-work-with-academia-on-pre-clinical-translational-gap-FKQS3QIU3NDS3GR2BKMMVM3LZQ\/?utm_source=chatgpt.com\">Insights<\/a>)<\/li>\n<\/ul>\n<p>This lack of infrastructure also makes the UK less attractive for <strong>domestic and overseas pharmaceutical investment<\/strong> in early R&amp;D. (<a title=\"The \nProductivity \nEngine\nMay 2024\" href=\"https:\/\/www.bidwells.co.uk\/globalassets\/report-documents\/productivity-engine\/the-productivity-engine-research-report-2024-21-august.pdf?utm_source=chatgpt.com\">Bidwells<\/a>)<\/p>\n<hr \/>\n<h3><span class=\"ez-toc-section\" id=\"3_Need_for_Better_Coordination\"><\/span>3. <strong>Need for Better Coordination<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<ul>\n<li>The review highlights that research groups and companies are not yet well-connected through a <strong>national translational strategy<\/strong>.<\/li>\n<li>The ABPI argues that <strong>closer collaboration between industry and academic labs<\/strong> is needed to accelerate uptake of new pre-clinical tools into real drug discovery.<\/li>\n<\/ul>\n<p>The ABPI also proposed the idea of a <strong>\u201ctranslational models hub\u201d<\/strong> \u2014 a shared centre to help scale and validate these new, human-relevant models \u2014 which has been referenced in government strategy documents. (<a title=\"ABPI launch report to bridge UK\u2019s drug discovery gap\" href=\"https:\/\/www.emjreviews.com\/emj-gold\/news\/abpi-launch-report-to-bridge-uks-drug-discovery-gap\/?utm_source=chatgpt.com\">European Medical Journal<\/a>)<\/p>\n<hr \/>\n<h2><span class=\"ez-toc-section\" id=\"_Impacts_on_UK_Innovation\"><\/span>\u00a0Impacts on UK Innovation<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"_Slowed_Medicine_Discovery\"><\/span>\u00a0Slowed Medicine Discovery<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Because pre-clinical models struggle to predict human responses, <strong>research that could lead to new drugs gets delayed or derailed<\/strong>, increasing costs and extending time to clinical trials and market. (<a title=\"From models to medicines:\" href=\"https:\/\/www.abpi.org.uk\/media\/033jwbjj\/models-to-medicines-feb-2026.pdf?utm_source=chatgpt.com\">ABPI<\/a>)<\/p>\n<h3><span class=\"ez-toc-section\" id=\"_Reduced_Competitiveness\"><\/span>\u00a0Reduced Competitiveness<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Industry feedback and broader reports show that:<\/p>\n<ul>\n<li>UK life sciences investment and R&amp;D productivity have been <strong>lagging behind competitors<\/strong> like the US and EU nations.<\/li>\n<li>Poor pre-clinical infrastructure is part of a wider set of challenges \u2014 including regulatory uncertainty and declining clinical trial activity \u2014 that reduce UK competitiveness in biotech innovation. (<a title=\"The \nProductivity \nEngine\nMay 2024\" href=\"https:\/\/www.bidwells.co.uk\/globalassets\/report-documents\/productivity-engine\/the-productivity-engine-research-report-2024-21-august.pdf?utm_source=chatgpt.com\">Bidwells<\/a>)<\/li>\n<\/ul>\n<hr \/>\n<h2><span class=\"ez-toc-section\" id=\"_Case-Level_Insights\"><\/span>\u00a0Case-Level Insights<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>While the ABPI report is not a \u201ccase study report,\u201d it does include <strong>examples of model categories where improvement could help<\/strong>:<\/p>\n<h3><span class=\"ez-toc-section\" id=\"_Human-Relevant_In_Vitro_Models\"><\/span>\u00a0Human-Relevant In Vitro Models<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Modern cell- and tissue-based systems \u2014 including organ-on-chip technologies \u2014 offer better human biology simulation than traditional animal models, but:<\/p>\n<ul>\n<li>They are still <strong>under-developed or not routinely adopted<\/strong> by industry.<\/li>\n<li>These models require <strong>specialised setups and validation pathways<\/strong> before regulators (like the UK Medicines and Healthcare products Regulatory Agency) will accept data from them. (<a title=\"From models to medicines:\" href=\"https:\/\/www.abpi.org.uk\/media\/033jwbjj\/models-to-medicines-feb-2026.pdf?utm_source=chatgpt.com\">ABPI<\/a>)<\/li>\n<\/ul>\n<h3><span class=\"ez-toc-section\" id=\"_Computer-Based_Modelling\"><\/span>\u00a0Computer-Based Modelling<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>In silico approaches show promise for early drug screening and safety prediction, but uptake is limited due to <strong>lack of standardised frameworks and industry partnerships<\/strong>. (<a title=\"From models to medicines:\" href=\"https:\/\/www.abpi.org.uk\/media\/033jwbjj\/models-to-medicines-feb-2026.pdf?utm_source=chatgpt.com\">ABPI<\/a>)<\/p>\n<hr \/>\n<h2><span class=\"ez-toc-section\" id=\"_Reactions_Expert_Comments\"><\/span>\u00a0Reactions &amp; Expert Comments<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"_Industry_Experts\"><\/span>\u00a0Industry Experts<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>A recent analysis noted that although UK academic innovation is strong, there\u2019s a <strong>\u201ctranslational readiness gap\u201d<\/strong> between academic discoveries and industry-ready tools \u2014 meaning many technologies never make it into practice without better coordination. (<a title=\"ABPI launch report to bridge UK\u2019s drug discovery gap\" href=\"https:\/\/www.emjreviews.com\/emj-gold\/news\/abpi-launch-report-to-bridge-uks-drug-discovery-gap\/?utm_source=chatgpt.com\">European Medical Journal<\/a>)<\/p>\n<p>Industry commentators also emphasise the urgency of:<\/p>\n<ul>\n<li>Increasing <strong>cross-sector collaboration<\/strong><\/li>\n<li>Streamlining <strong>validation and regulatory pathways<\/strong><\/li>\n<li>Investing in infrastructure that can support more predictive models<\/li>\n<\/ul>\n<p>These changes could not only speed up drug development but also help attract more <strong>investment and R&amp;D projects<\/strong> back into the UK life sciences sector. (<a title=\"UK Report Highlights Need for Improved Collaboration to Address Shortcomings in Preclinical Testing Models\" href=\"https:\/\/www.geneonline.com\/uk-report-highlights-need-for-improved-collaboration-to-address-shortcomings-in-preclinical-testing-models\/?utm_source=chatgpt.com\">geneonline.com<\/a>)<\/p>\n<hr \/>\n<h2><span class=\"ez-toc-section\" id=\"_Why_It_Matters_for_the_UK\"><\/span>\u00a0Why It Matters for the UK<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Addressing pre-clinical model limitations is seen as critical because:<\/p>\n<ul>\n<li>It affects the <strong>early stages of drug discovery<\/strong>, where innovation begins.<\/li>\n<li>Improving model predictivity can <strong>reduce late-stage failures<\/strong> and costs.<\/li>\n<li>A more efficient translational pipeline strengthens the UK\u2019s position as a <strong>competitive global hub for life sciences<\/strong> \u2014 a stated goal in government strategy planning. (<a title=\"From models to medicines:\" href=\"https:\/\/www.abpi.org.uk\/media\/033jwbjj\/models-to-medicines-feb-2026.pdf?utm_source=chatgpt.com\">ABPI<\/a>)<\/li>\n<\/ul>\n<hr \/>\n<h2><span class=\"ez-toc-section\" id=\"_In_Summary\"><\/span>\u00a0In Summary<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<ul>\n<li>An ABPI-backed review warns that limitations in current <strong>pre-clinical models<\/strong> are slowing translation of scientific discovery into new medicines in the UK. (<a title=\"UK: Industry Needs To Work With Academia On Pre-Clinical \u2018Translational Gap\u2019\" href=\"https:\/\/insights.citeline.com\/pink-sheet\/r-and-d\/uk-industry-needs-to-work-with-academia-on-pre-clinical-translational-gap-FKQS3QIU3NDS3GR2BKMMVM3LZQ\/?utm_source=chatgpt.com\">Insights<\/a>)<\/li>\n<li>Key issues include <strong>poor predictivity<\/strong>, <strong>infrastructure gaps<\/strong>, and weak <strong>industry-academia collaboration<\/strong>. (<a title=\"From models to medicines:\" href=\"https:\/\/www.abpi.org.uk\/media\/033jwbjj\/models-to-medicines-feb-2026.pdf?utm_source=chatgpt.com\">ABPI<\/a>)<\/li>\n<li>The review calls for coordinated strategies, better validation systems, and national-level investment to ensure that pr\n<p>Here\u2019s a <strong>detailed, up-to-date breakdown<\/strong> of the <strong>ABPI report warning that pre-clinical model limitations are slowing UK innovation<\/strong>, including <strong>illustrative case-driven insights and expert community comments<\/strong> on why this matters for medicines development in the UK. (<a title=\"From models to medicines: a landscape review of human-relevant pre-clinical model development in the UK\" href=\"https:\/\/www.abpi.org.uk\/publications\/from-models-to-medicines-a-landscape-review-of-human-relevant-pre-clinical-model-development-in-the-uk\/?utm_source=chatgpt.com\">ABPI<\/a>)<\/p>\n<hr \/>\n<h2><span class=\"ez-toc-section\" id=\"_What_the_ABPI_Report_Says\"><\/span>\u00a0What the ABPI Report Says<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The <strong>Association of the British Pharmaceutical Industry (ABPI)<\/strong> commissioned a <strong>landscape review<\/strong> of pre-clinical models in the UK to understand how well research systems predict human biology and support drug discovery. The key conclusion is that <strong>limitations in pre-clinical models are impeding innovation and slowing progress toward new medicines<\/strong>. (<a title=\"From models to medicines: a landscape review of human-relevant pre-clinical model development in the UK\" href=\"https:\/\/www.abpi.org.uk\/publications\/from-models-to-medicines-a-landscape-review-of-human-relevant-pre-clinical-model-development-in-the-uk\/?utm_source=chatgpt.com\">ABPI<\/a>)<\/p>\n<p>Pre-clinical models (the lab systems used before clinical trials, such as cell cultures, computer models, and animal systems) are vital in:<\/p>\n<ul>\n<li>identifying disease mechanisms,<\/li>\n<li>selecting promising drug candidates, and<\/li>\n<li>predicting human responses before clinical trials. (<a title=\"From models to medicines: a landscape review of human-relevant pre-clinical model development in the UK\" href=\"https:\/\/www.abpi.org.uk\/publications\/from-models-to-medicines-a-landscape-review-of-human-relevant-pre-clinical-model-development-in-the-uk\/?utm_source=chatgpt.com\">ABPI<\/a>)<\/li>\n<\/ul>\n<p>But many models <strong>don\u2019t reliably mimic human biology<\/strong>, leading to drug failures later in development \u2014 which slows innovation and raises costs. (<a title=\"From models to medicines: a landscape review of human-relevant pre-clinical model development in the UK\" href=\"https:\/\/www.abpi.org.uk\/publications\/from-models-to-medicines-a-landscape-review-of-human-relevant-pre-clinical-model-development-in-the-uk\/?utm_source=chatgpt.com\">ABPI<\/a>)<\/p>\n<hr \/>\n<h2><span class=\"ez-toc-section\" id=\"_Key_Findings_Translational_Challenges\"><\/span>\u00a0Key Findings &amp; Translational Challenges<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"_1_%E2%80%9CTranslational_Gap%E2%80%9D_from_Lab_to_Industry\"><\/span>\u00a01. \u201cTranslational Gap\u201d from Lab to Industry<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The report finds a <strong>gap between academic model development and models that are reliable enough for use in commercial drug discovery<\/strong>. While UK labs are generating innovative human-relevant models \u2014 such as advanced cell systems and computer simulations \u2014 <strong>many are not yet mature enough to replace traditional methods in industry settings<\/strong>. (<a title=\"From models to medicines:\" href=\"https:\/\/www.abpi.org.uk\/media\/033jwbjj\/models-to-medicines-feb-2026.pdf?utm_source=chatgpt.com\">ABPI<\/a>)<\/p>\n<p>Problems include:<\/p>\n<ul>\n<li>lack of <strong>standardisation<\/strong>,<\/li>\n<li>difficulty <strong>scaling models<\/strong>, and<\/li>\n<li>insufficient <strong>validation and reproducibility<\/strong> for regulatory or commercial use. (<a title=\"From models to medicines:\" href=\"https:\/\/www.abpi.org.uk\/media\/033jwbjj\/models-to-medicines-feb-2026.pdf?utm_source=chatgpt.com\">ABPI<\/a>)<\/li>\n<\/ul>\n<p>Experts interviewed for the report stressed that for a model to be \u201cindustry-ready,\u201d it must reliably mimic human biology, be robust, and be usable at scale \u2014 and most current UK models still need further development. (<a title=\"From models to medicines:\" href=\"https:\/\/www.abpi.org.uk\/media\/033jwbjj\/models-to-medicines-feb-2026.pdf?utm_source=chatgpt.com\">ABPI<\/a>)<\/p>\n<hr \/>\n<h2><span class=\"ez-toc-section\" id=\"_Case-Driven_Insights\"><\/span>\u00a0Case-Driven Insights<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The report doesn\u2019t publish named company case studies, but it <em>does<\/em> highlight <strong>real-world patterns in how model limitations affect innovation<\/strong>, including:<\/p>\n<h3><span class=\"ez-toc-section\" id=\"_Advanced_Human_Cell_Models\"><\/span>\u00a0Advanced Human Cell Models<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>3D cultures, organoids and organ-on-chip systems<\/strong> are being developed in UK labs to better represent human tissues than simple cell cultures. These can offer more accurate insights into how drugs might work in people, especially for complex diseases. (<a title=\"From models to medicines:\" href=\"https:\/\/www.abpi.org.uk\/media\/033jwbjj\/models-to-medicines-feb-2026.pdf?utm_source=chatgpt.com\">ABPI<\/a>)<\/p>\n<p>However, barriers include:<\/p>\n<ul>\n<li>difficulties obtaining <strong>well-characterised human cell sources<\/strong>,<\/li>\n<li>variability in how models behave across labs, and<\/li>\n<li>challenges in <strong>interpreting and standardising output<\/strong>. (<a title=\"From models to medicines:\" href=\"https:\/\/www.abpi.org.uk\/media\/033jwbjj\/models-to-medicines-feb-2026.pdf?utm_source=chatgpt.com\">ABPI<\/a>)<\/li>\n<\/ul>\n<p>These kinds of limitations mean that even promising academic breakthroughs often <em>don\u2019t translate<\/em> into tools that industry can use routinely for drug candidate selection.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"_In_Silico_Computer_Modelling\"><\/span>\u00a0In Silico (Computer) Modelling<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Computer-based simulations are also advancing, offering a way to screen drug candidates and predict responses, but adoption is <strong>limited by lack of standard regulatory frameworks<\/strong> and a need for more cross-sector collaboration on how results are interpreted. (<a title=\"From models to medicines:\" href=\"https:\/\/www.abpi.org.uk\/media\/033jwbjj\/models-to-medicines-feb-2026.pdf?utm_source=chatgpt.com\">ABPI<\/a>)<\/p>\n<hr \/>\n<h2><span class=\"ez-toc-section\" id=\"_Expert_Stakeholder_Comments\"><\/span>\u00a0Expert &amp; Stakeholder Comments<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"_Academic_Industry_Experts\"><\/span>\u00a0Academic &amp; Industry Experts<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>In stakeholder interviews conducted as part of the ABPI review, scientists from both academia and industry noted that:<\/p>\n<ul>\n<li>Many <strong>academic models are scientifically innovative<\/strong> but not yet validated for industry use.<\/li>\n<li>Lack of <strong>shared standards<\/strong>, <strong>infrastructure<\/strong>, and <strong>scale-up pathways<\/strong> are slowing adoption by commercial drug developers.<\/li>\n<li>Even where a model shows promise, <strong>regulatory acceptance is unclear or slow<\/strong>, which discourages industry investment. (<a title=\"From models to medicines:\" href=\"https:\/\/www.abpi.org.uk\/media\/033jwbjj\/models-to-medicines-feb-2026.pdf?utm_source=chatgpt.com\">ABPI<\/a>)<\/li>\n<\/ul>\n<p>This \u201ctranslational readiness gap\u201d means that scientific discoveries don\u2019t transition smoothly into tools that support new drug development, contributing to slower innovation timelines overall.<\/p>\n<hr \/>\n<h2><span class=\"ez-toc-section\" id=\"_Community_Commentary_Context\"><\/span>\u00a0Community &amp; Commentary Context<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Outside of the formal report itself, broader discussions in scientific and industry forums point to related frustrations:<\/p>\n<ul>\n<li>Some UK life sciences professionals argue that <strong>innovation is at risk of being less competitive internationally<\/strong> if predictive models aren\u2019t scaled effectively. This echoes concerns in the ABPI report. (industry sentiment from professional communities)<\/li>\n<li>Others note that <strong>greater collaboration across academic, industry and regulatory bodies<\/strong> could help bridge the divide between discovery research and practical application. (broader scientific feedback)<\/li>\n<\/ul>\n<hr \/>\n<h2><span class=\"ez-toc-section\" id=\"_What_This_Means_for_UK_Innovation\"><\/span>\u00a0What This Means for UK Innovation<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The ABPI\u2019s findings highlight several systemic challenges that could slow UK life sciences progress if not addressed:<\/p>\n<h3><span class=\"ez-toc-section\" id=\"_Slower_Time-to-Clinic\"><\/span>\u00a0Slower Time-to-Clinic<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>When pre-clinical models don\u2019t predict human responses well, drug candidates may fail late in the development pipeline \u2014 wasting time and resources and delaying new treatments.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"_Reduced_Investment_Appeal\"><\/span>\u00a0Reduced Investment Appeal<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Pharmaceutical companies may be <strong>less inclined to invest in UK R&amp;D<\/strong> if they can\u2019t rely on locally developed models or infrastructure to support early-stage drug work.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"_Missed_Collaborative_Potential\"><\/span>\u00a0Missed Collaborative Potential<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The UK has <strong>research strengths<\/strong>, but without coordinated pathways to move models from academic labs to industry and regulatory use, many breakthroughs may remain confined to publications rather than contributing to real medicines. (<a title=\"UK opportunity to accelerate development of new medicines\" href=\"https:\/\/www.abpi.org.uk\/media\/news\/2026\/february\/uk-opportunity-to-accelerate-development-of-new-medicines\/?utm_source=chatgpt.com\">ABPI<\/a>)<\/p>\n<hr \/>\n<h2><span class=\"ez-toc-section\" id=\"_In_Summary-2\"><\/span>\u00a0In Summary<span class=\"ez-toc-section-end\"><\/span><\/h2>\n<ul>\n<li>An <strong>ABPI-commissioned report<\/strong> warns that current <strong>limitations in pre-clinical models<\/strong> (like insufficient validation, standardisation, and infrastructure) are <strong>slowing innovation in UK medicine development<\/strong>. (<a title=\"From models to medicines: a landscape review of human-relevant pre-clinical model development in the UK\" href=\"https:\/\/www.abpi.org.uk\/publications\/from-models-to-medicines-a-landscape-review-of-human-relevant-pre-clinical-model-development-in-the-uk\/?utm_source=chatgpt.com\">ABPI<\/a>)<\/li>\n<li>Although there is strong scientific capability, many <strong>human-relevant models developed in UK labs aren\u2019t yet ready<\/strong> for reliable industry or regulatory use. (<a title=\"From models to medicines:\" href=\"https:\/\/www.abpi.org.uk\/media\/033jwbjj\/models-to-medicines-feb-2026.pdf?utm_source=chatgpt.com\">ABPI<\/a>)<\/li>\n<li>Experts comment that improving <strong>collaboration, validation pathways and shared infrastructure<\/strong> is essential to translate academic discoveries into tools that can speed up drug discovery and benefit patients. (<a title=\"UK opportunity to accelerate development of new medicines\" href=\"https:\/\/www.abpi.org.uk\/media\/news\/2026\/february\/uk-opportunity-to-accelerate-development-of-new-medicines\/?utm_source=chatgpt.com\">ABPI<\/a>)<\/li>\n<\/ul>\n<hr \/>\n<p>&nbsp;<\/li>\n<\/ul>\n<hr \/>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>&nbsp; \u00a0What the ABPI Report Is About The ABPI and academic partners have published a landscape review of pre-clinical model development in the UK \u2014&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[10,6],"tags":[],"class_list":["post-991510","post","type-post","status-publish","format-standard","hentry","category-gb-news","category-uk-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.5 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>ABPI report warns preclinical model limitations are slowing UK innovation - UK News &amp; Updates<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ukpostcode.org\/content\/abpi-report-warns-preclinical-model-limitations-are-slowing-uk-innovation\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ABPI report warns preclinical model limitations are slowing UK innovation - UK News &amp; Updates\" \/>\n<meta property=\"og:description\" content=\"&nbsp; \u00a0What the ABPI Report Is About The ABPI and academic partners have published a landscape review of pre-clinical model development in the UK \u2014...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ukpostcode.org\/content\/abpi-report-warns-preclinical-model-limitations-are-slowing-uk-innovation\/\" \/>\n<meta property=\"og:site_name\" content=\"UK News &amp; Updates\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-20T13:03:03+00:00\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"7 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/ukpostcode.org\/content\/abpi-report-warns-preclinical-model-limitations-are-slowing-uk-innovation\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/ukpostcode.org\/content\/abpi-report-warns-preclinical-model-limitations-are-slowing-uk-innovation\/\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\/\/ukpostcode.org\/content\/#\/schema\/person\/5529805dee92503827c0c27ed13d55a3\"},\"headline\":\"ABPI report warns preclinical model limitations are slowing UK innovation\",\"datePublished\":\"2026-02-20T13:03:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ukpostcode.org\/content\/abpi-report-warns-preclinical-model-limitations-are-slowing-uk-innovation\/\"},\"wordCount\":1580,\"publisher\":{\"@id\":\"https:\/\/ukpostcode.org\/content\/#organization\"},\"articleSection\":[\"GB News\",\"UK News\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/ukpostcode.org\/content\/abpi-report-warns-preclinical-model-limitations-are-slowing-uk-innovation\/\",\"url\":\"https:\/\/ukpostcode.org\/content\/abpi-report-warns-preclinical-model-limitations-are-slowing-uk-innovation\/\",\"name\":\"ABPI report warns preclinical model limitations are slowing UK innovation - UK News &amp; Updates\",\"isPartOf\":{\"@id\":\"https:\/\/ukpostcode.org\/content\/#website\"},\"datePublished\":\"2026-02-20T13:03:03+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/ukpostcode.org\/content\/abpi-report-warns-preclinical-model-limitations-are-slowing-uk-innovation\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ukpostcode.org\/content\/abpi-report-warns-preclinical-model-limitations-are-slowing-uk-innovation\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ukpostcode.org\/content\/abpi-report-warns-preclinical-model-limitations-are-slowing-uk-innovation\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ukpostcode.org\/content\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ABPI report warns preclinical model limitations are slowing UK innovation\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/ukpostcode.org\/content\/#website\",\"url\":\"https:\/\/ukpostcode.org\/content\/\",\"name\":\"UK News &amp; Updates\",\"description\":\"UK Post Code\",\"publisher\":{\"@id\":\"https:\/\/ukpostcode.org\/content\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/ukpostcode.org\/content\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/ukpostcode.org\/content\/#organization\",\"name\":\"UK News &amp; Updates\",\"url\":\"https:\/\/ukpostcode.org\/content\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/ukpostcode.org\/content\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/ukpostcode.org\/content\/wp-content\/uploads\/2023\/09\/cropped-uk-logo-1.png\",\"contentUrl\":\"https:\/\/ukpostcode.org\/content\/wp-content\/uploads\/2023\/09\/cropped-uk-logo-1.png\",\"width\":307,\"height\":85,\"caption\":\"UK News &amp; Updates\"},\"image\":{\"@id\":\"https:\/\/ukpostcode.org\/content\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/ukpostcode.org\/content\/#\/schema\/person\/5529805dee92503827c0c27ed13d55a3\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/ukpostcode.org\/content\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/6aac6e3af4be1d6689e924bbaccd84fc0cc6c5f6680490dc6f0a1f09b87d57f1?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/6aac6e3af4be1d6689e924bbaccd84fc0cc6c5f6680490dc6f0a1f09b87d57f1?s=96&d=mm&r=g\",\"caption\":\"admin\"},\"sameAs\":[\"https:\/\/ukpostcode.org\/content\"],\"url\":\"https:\/\/ukpostcode.org\/content\/author\/admin\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ABPI report warns preclinical model limitations are slowing UK innovation - UK News &amp; Updates","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ukpostcode.org\/content\/abpi-report-warns-preclinical-model-limitations-are-slowing-uk-innovation\/","og_locale":"en_US","og_type":"article","og_title":"ABPI report warns preclinical model limitations are slowing UK innovation - UK News &amp; Updates","og_description":"&nbsp; \u00a0What the ABPI Report Is About The ABPI and academic partners have published a landscape review of pre-clinical model development in the UK \u2014...","og_url":"https:\/\/ukpostcode.org\/content\/abpi-report-warns-preclinical-model-limitations-are-slowing-uk-innovation\/","og_site_name":"UK News &amp; Updates","article_published_time":"2026-02-20T13:03:03+00:00","author":"admin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin","Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ukpostcode.org\/content\/abpi-report-warns-preclinical-model-limitations-are-slowing-uk-innovation\/#article","isPartOf":{"@id":"https:\/\/ukpostcode.org\/content\/abpi-report-warns-preclinical-model-limitations-are-slowing-uk-innovation\/"},"author":{"name":"admin","@id":"https:\/\/ukpostcode.org\/content\/#\/schema\/person\/5529805dee92503827c0c27ed13d55a3"},"headline":"ABPI report warns preclinical model limitations are slowing UK innovation","datePublished":"2026-02-20T13:03:03+00:00","mainEntityOfPage":{"@id":"https:\/\/ukpostcode.org\/content\/abpi-report-warns-preclinical-model-limitations-are-slowing-uk-innovation\/"},"wordCount":1580,"publisher":{"@id":"https:\/\/ukpostcode.org\/content\/#organization"},"articleSection":["GB News","UK News"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/ukpostcode.org\/content\/abpi-report-warns-preclinical-model-limitations-are-slowing-uk-innovation\/","url":"https:\/\/ukpostcode.org\/content\/abpi-report-warns-preclinical-model-limitations-are-slowing-uk-innovation\/","name":"ABPI report warns preclinical model limitations are slowing UK innovation - UK News &amp; Updates","isPartOf":{"@id":"https:\/\/ukpostcode.org\/content\/#website"},"datePublished":"2026-02-20T13:03:03+00:00","breadcrumb":{"@id":"https:\/\/ukpostcode.org\/content\/abpi-report-warns-preclinical-model-limitations-are-slowing-uk-innovation\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ukpostcode.org\/content\/abpi-report-warns-preclinical-model-limitations-are-slowing-uk-innovation\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/ukpostcode.org\/content\/abpi-report-warns-preclinical-model-limitations-are-slowing-uk-innovation\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ukpostcode.org\/content\/"},{"@type":"ListItem","position":2,"name":"ABPI report warns preclinical model limitations are slowing UK innovation"}]},{"@type":"WebSite","@id":"https:\/\/ukpostcode.org\/content\/#website","url":"https:\/\/ukpostcode.org\/content\/","name":"UK News &amp; Updates","description":"UK Post Code","publisher":{"@id":"https:\/\/ukpostcode.org\/content\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ukpostcode.org\/content\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/ukpostcode.org\/content\/#organization","name":"UK News &amp; Updates","url":"https:\/\/ukpostcode.org\/content\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ukpostcode.org\/content\/#\/schema\/logo\/image\/","url":"https:\/\/ukpostcode.org\/content\/wp-content\/uploads\/2023\/09\/cropped-uk-logo-1.png","contentUrl":"https:\/\/ukpostcode.org\/content\/wp-content\/uploads\/2023\/09\/cropped-uk-logo-1.png","width":307,"height":85,"caption":"UK News &amp; Updates"},"image":{"@id":"https:\/\/ukpostcode.org\/content\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/ukpostcode.org\/content\/#\/schema\/person\/5529805dee92503827c0c27ed13d55a3","name":"admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ukpostcode.org\/content\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/6aac6e3af4be1d6689e924bbaccd84fc0cc6c5f6680490dc6f0a1f09b87d57f1?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/6aac6e3af4be1d6689e924bbaccd84fc0cc6c5f6680490dc6f0a1f09b87d57f1?s=96&d=mm&r=g","caption":"admin"},"sameAs":["https:\/\/ukpostcode.org\/content"],"url":"https:\/\/ukpostcode.org\/content\/author\/admin\/"}]}},"_links":{"self":[{"href":"https:\/\/ukpostcode.org\/content\/wp-json\/wp\/v2\/posts\/991510","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ukpostcode.org\/content\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ukpostcode.org\/content\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ukpostcode.org\/content\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/ukpostcode.org\/content\/wp-json\/wp\/v2\/comments?post=991510"}],"version-history":[{"count":1,"href":"https:\/\/ukpostcode.org\/content\/wp-json\/wp\/v2\/posts\/991510\/revisions"}],"predecessor-version":[{"id":991511,"href":"https:\/\/ukpostcode.org\/content\/wp-json\/wp\/v2\/posts\/991510\/revisions\/991511"}],"wp:attachment":[{"href":"https:\/\/ukpostcode.org\/content\/wp-json\/wp\/v2\/media?parent=991510"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ukpostcode.org\/content\/wp-json\/wp\/v2\/categories?post=991510"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ukpostcode.org\/content\/wp-json\/wp\/v2\/tags?post=991510"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}